Lead Product(s): Allogeneic iPSC-derived cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Itochu Chemical Frontier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2020
Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.